CPSI VS DNTH Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividendSentiment
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividendSentiment

Performance

CPSI
10/100

CPSI returned -59.89% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

DNTH
26/100

DNTH returned 11.54% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 26 of 100.

Analyst Price Targets

CPSI
52/100

11 analysts offer 12-month price targets for CPSI. Together, they have an average target of 0, the most optimistic target put CPSI at 0 within 12-months and the most pessimistic has CPSI at 0.

DNTH
81/100

4 analysts offer 12-month price targets for DNTH. Together, they have an average target of 0, the most optimistic target put DNTH at 0 within 12-months and the most pessimistic has DNTH at 0.

Technicals

CPSI
14/100

CPSI receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

DNTH

"Technicals" not found for DNTH

Earnings

CPSI
10/100

CPSI has missed earnings 8 times in the last 20 quarters.

DNTH
41/100

DNTH has missed earnings 2 times in the last 20 quarters.

Profit

CPSI
64/100

Out of the last 20 quarters, CPSI has had 18 profitable quarters and has increased their profits year over year on 7 of them.

DNTH

"Profit" not found for DNTH

Volatility

CPSI
31/100

CPSI has had a lower than average amount of volatility over the last 12 months giving it a score of 30 of 100.

DNTH
88/100

DNTH has had a higher than average amount of volatility over the last 12 months giving it a score of 87 of 100.

Dividend

CPSI
37/100

CPSI's most recent dividend was $0.10 per share, based on a share price of $11.36. It was a payout ratio of 18.57% compared to their total earnings.

DNTH

"Dividend" not found for DNTH

Sentiment

CPSI

"Sentiment" not found for CPSI

DNTH
65/100

DNTH had a bullish sentiment score of 65.49% across Twitter and StockTwits over the last 12 months. It had an average of 1.64 posts, 0.07 comments, and 0.09 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Computer Programs & Systems In Summary

Nasdaq / CPSI
Healthcare
Health Information Services
Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital, and provide software applications. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement, and encoder solutions. It serves community hospitals and physician clinics, skilled nursing, and assisted living facilities. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.

Dianthus Therapeutics, Inc. Common Stock Summary

Nasdaq / DNTH
Healthcare
Biotechnology
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.